Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis

Archives of Pediatrics and Adolescent Medicine

Volumn 165, Issue 9, 2011, Pages 847-856

  Treggiari, Miriam M ^a   Retsch Bogart, George ^c   Mayer Hamblett, Nicole ^b   Khan, Umer ^a   Kulich, Michal ^d   Kronmal, Richard ^a   Williams, Judy ^a   Hiatt, Peter ^e   Gibson, Ronald L ^b   Spencer, Terry ^f   Orenstein, David ^g   Chatfield, Barbara A ^h   Froh, Deborah K ⁱ   Burns, Jane L ^b   Rosenfeld, Margaret ^b   Ramsey, Bonnie W ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d CHARLES UNIVERSITY   (Czech Republic)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f BOSTON CHILDREN S HOSPITAL   (United States)

^g CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^h UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; PLACEBO; TOBRAMYCIN;

ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM CULTURE; BACTERIUM DETECTION; CHILD; CHILDHOOD DISEASE; CONTROLLED STUDY; COUGHING; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; UNITED STATES;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; CHILD; CHILD, PRESCHOOL; CIPROFLOXACIN; CYSTIC FIBROSIS; FEMALE; HUMANS; INFANT; MALE; PLACEBOS; PROPORTIONAL HAZARDS MODELS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TOBRAMYCIN; TREATMENT OUTCOME; UNITED STATES;

EID: 80052511405     PISSN: 10724710     EISSN: 15383628     Source Type: Journal    
DOI: 10.1001/archpediatrics.2011.136     Document Type: Article

References (47)

1. Döring G., Conway S.P., Heijerman H.G., et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J. 2000;16(4):749-767.
2. Parad R.B., Gerard C.J., Zurakowski D., Nichols D.P., Pier G.B. Pulmonary outcome in cystic fibrosis is influenced primarily by mucoid Pseudomonas aeruginosa infection and immune status and only modestly by genotype. Infect Immun. 1999;67(9):4744-4750. (Pubitemid 29400459)
3. Henry R.L., Mellis C.M., Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol. 1992;12(3):158-161.
4. Emerson J., Rosenfeld M., McNamara S., Ramsey B., Gibson R.L. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol. 2002;34(2):91-100. (Pubitemid 34809519)
5. Rosenfeld M., Gibson R.L., McNamara S., et al. Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr Pulmonol. 2001;32(5):356-366. (Pubitemid 33015652)
6. Cystic Fibrosis Foundation Patient Registry 2008 Annual Data Report to the Center Directors. Bethesda, MD: Cystic Fibrosis Foundation; 2009.
7. Burns J.L., Gibson R.L., McNamara S., et al. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J Infect Dis. 2001;183(3):444-452. (Pubitemid 32105604)
8. Costerton J.W., Stewart P.S., Greenberg E.P. Bacterial biofilms: a common cause of persistent infections. Science. 1999;284(5418):1318-1322. (Pubitemid 29289651)
9. Li Z., Kosorok M.R., Farrell P.M., et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA. 2005;293(5):581-588. (Pubitemid 40171240)
10. Singh P.K., Schaefer A.L., Parsek M.R., Moninger T.O., Welsh M.J., Greenberg E.P. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature. 2000;407(6805):762-764.
11. West S.E., Zeng L., Lee B.L., et al. Respiratory infections with Pseudomonas aeruginosa in children with cystic fibrosis: early detection by serology and assessment of risk factors. JAMA. 2002;287(22):2958-2967. (Pubitemid 34619999)
12. Sagel S.D., Gibson R.L., Emerson J., et al Inhaled Tobramycin in Young Children Study Group; Cystic Fibrosis Foundation Therapeutics Development Network. Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis. J Pediatr. 2009;154(2):183-188.
13. Armstrong D.S., Grimwood K., Carlin J.B., Carzino R., Olinsky A., Phelan P.D. Bronchoalveolar lavage or oropharyngeal cultures to identify lower respiratory pathogens in infants with cystic fibrosis. Pediatr Pulmonol. 1996;21(5):267-275. (Pubitemid 26159822)
14. Dakin C.J., Numa A.H., Wang H., Morton J.R., Vertzyas C.C., Henry R.L. Inflammation, infection, and pulmonary function in infants and young children with cystic fibrosis. Am J Respir Crit Care Med. 2002;165(7):904-910. (Pubitemid 34774655)
15. Lee T.W., Brownlee K.G., Conway S.P., Denton M., Littlewood J.M. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros. 2003;2(1):29-34. (Pubitemid 36857407)
16. Ratjen F., Munck A., Kho P., Angyalosi G.; ELITE Study Group. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax. 2010;65(4):286-291.
17. Valerius N.H., Koch C., Høiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet. 1991;338(8769):725-726.
18. Wiesemann H.G., Steinkamp G., Ratjen F., et al. Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Pediatr Pulmonol. 1998;25(2):88-92. (Pubitemid 28110583)
19. Gibson R.L., Emerson J., McNamara S., et al Cystic Fibrosis Therapeutics Development Network Study Group. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med. 2003;167(6):841-849. (Pubitemid 36801771)
20. Frederiksen B., Koch C., Høiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol. 1997;23(5):330-335. (Pubitemid 27225208)
21. Munck A., Bonacorsi S., Mariani-Kurkdjian P., et al. Genotypic characterization of Pseudomonas aeruginosa strains recovered from patients with cystic fibrosis after initial and subsequent colonization. Pediatr Pulmonol. 2001;32(4):288-292. (Pubitemid 32938877)
22. Taccetti G., Campana S., Festini F., Mascherini M., Döring G. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur Respir J. 2005;26(3):458-461. (Pubitemid 41264209)
23. Langton Hewer S.C., Smyth A.R. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev. 2009;(4):CD004197.
24. Döring G., Hoiby N.; Consensus Study Group. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cyst Fibros. 2004;3(2):67-91. (Pubitemid 38987019)
25. Treggiari M.M., Rosenfeld M., Retsch-Bogart G., Gibson R., Ramsey B. Approach to eradication of initial Pseudomonas aeruginosa infection in children with cystic fibrosis. Pediatr Pulmonol. 2007;42(9):751-756. (Pubitemid 47580800)
26. Lee T.W. Eradication of early Pseudomonas infection in cystic fibrosis. Chron Respir Dis. 2009;6(2):99-107.
27. Rosenfeld M., Emerson J., Williams-Warren J., et al. Defining a pulmonary exacerbation in cystic fibrosis. J Pediatr. 2001;139(3):359-365. (Pubitemid 32889511)
28. Pamukcu A., Bush A., Buchdahl R. Effects of Pseudomonas aeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosis. Pediatr Pulmonol. 1995;19(1):10-15.
29. Hansen C.R., Pressler T., Høiby N. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. J Cyst Fibros. 2008;7(6):523-530.
30. Treggiari M.M., Rosenfeld M., Mayer-Hamblett N., et al EPIC Study Group. Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study. Contemp Clin Trials. 2009;30(3):256-268.
31. Rosenstein B.J., Cutting G.R.; Cystic Fibrosis Foundation Consensus Panel. The diagnosis of cystic fibrosis: a consensus statement. J Pediatr. 1998;132(4):589-595. (Pubitemid 28194575)
32. Bosso J.A. Use of ciprofloxacin in cystic fibrosis patients. Am JMed. 1989;87(5A):123S-127S. (Pubitemid 20005163)
33. Schaad U.B., Rubio T., Kanga J., Stutman H.R., Smith A. Panel discussion: antimicrobial therapy in pediatric cystic fibrosis patients. Pediatr Infect Dis. 1997;16(1):123-126. doi:10.1097/00006454-199701000-00035.
34. Burns J.L., Emerson J., Stapp J.R., et al. Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin Infect Dis. 1998;27(1):158-163. (Pubitemid 28334435)
35. Beydon N., Davis S.D., Lombardi E., et al American Thoracic Society/European Respiratory Society Working Group on Infant and Young Children Pulmonary Function Testing. An official American Thoracic Society/European Respiratory Society statement: pulmonary function testing in preschool children. Am J Respir Crit Care Med. 2007;175(12):1304-1345. (Pubitemid 46905757)
36. Diggle P.J., Haegerty P., Liang K.Y., Zeger S.L. Analysis of Longitudinal Data. 2nd ed. Oxford, England: Oxford University Press; 2002.
37. Ramsey B.W., Pepe M.S., Quan J.M., et al Cystic Fibrosis Inhaled Tobramycin Study Group. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med. 1999;340(1):23-30. (Pubitemid 29024680)
38. Goss C.H., Mayer-Hamblett N., Aitken M.L., Rubenfeld G.D., Ramsey B.W. Association between Stenotrophomonas maltophilia and lung function in cystic fibrosis. Thorax. 2004;59(11):955-959. (Pubitemid 39490780)
39. Waters V., Yau Y., Prasad S., et al. Stenotrophomonas maltophilia in cystic fibrosis: serologic response and effect on lung disease. Am J Respir Crit Care Med. 2011;183(5):635-640.
40. Fuchs H.J., Borowitz D.S., Christiansen D.H., et al The Pulmozyme Study Group. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med. 1994;331(10):637-642. (Pubitemid 24276863)
41. Saiman L., Marshall B.C., Mayer-Hamblett N., et al Macrolide Study Group. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2003;290(13):1749-1756. (Pubitemid 37430625)
42. Thomassen M.J., Klinger J.D., Badger S.J., Van Heeckeren D.W., Stern R.C. Cultures of thoracotomy specimens confirm usefulness of sputum cultures in cystic fibrosis. J Pediatr. 1984;104(3):352-356. (Pubitemid 14160458)
43. Clinical Practice Guidelines for Cystic Fibrosis. Bethesda, MD: Cystic Fibrosis Foundation; 1997.
44. Rosenfeld M., Emerson J., Accurso F., et al. Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis. Pediatr Pulmonol. 1999;28(5):321-328. (Pubitemid 29523443)
45. Cystic Fibrosis Foundation Patient Registry 1999 Annual Data Report to the Center Directors. Bethesda, MD: Cystic Fibrosis Foundation; 2000.
46. Konstan M.W., Butler S.M., Schidlow D.V., Morgan W.J., Julius J.R., Johnson C.A.; Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Patterns of medical practice in cystic fibrosis, part II: use of therapies. Pediatr Pulmonol. 1999;28(4):248-254. (Pubitemid 29468458)
47. Rosenfeld M., Emerson J., McNamara S., et al EPIC Study Group Participating Clinical Sites. Baseline characteristics and factors associated with nutritional and pulmonary status at enrollment in the cystic fibrosis EPIC observational cohort. Pediatr Pulmonol. 2010;45(9):934-944.